• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GRAIL Inc.

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    SC 13G 1 gral_111124.htm PRIMECAP MANAGEMENT CO/CA/ gral_111124.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    GRAIL INC
    (Name of Issuer)
    COM
    (Title of Class of Securities)
    384747101
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 384747101
           
    1
    NAME OF REPORTING PERSON
    PRIMECAP Management Company
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    95-3868081
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    2,150,983
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    2,182,506
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,182,506
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.03%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 384747101
    ITEM 1(a). NAME OF ISSUER:
    GRAIL INC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    1525 O'BRIEN DRIVE, MENLO PARK, CA, 94025
    ITEM 2(a). NAME OF PERSON FILING:
    PRIMECAP Management Company
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    ITEM 2(c). CITIZENSHIP:
    U.S.A.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    COM
    ITEM 2(e). CUSIP NUMBER:
    384747101
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    2,182,506
    (b) Percent of class:
    7.03%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    PRIMECAP Management Company : 2,150,983
    (ii) shared power to vote or to direct the vote:
    PRIMECAP Management Company : 0
    (iii) sole power to dispose or direct the disposition of:
    PRIMECAP Management Company : 2,182,506
    (iv) shared power to dispose or to direct the disposition of:
    PRIMECAP Management Company : 0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not Applicable
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 384747101
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 11 2024
    PRIMECAP Management Company
    By:
    /s/ Jorge A. Rodriguez
    Name:
    Jorge A. Rodriguez
    Title:
    Deputy Chief Compliance Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $GRAL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Ofman Joshua J. sold $134,548 worth of shares (4,202 units at $32.02), decreasing direct ownership by 0.85% to 487,874 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    8/20/25 4:24:55 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Chief Financial Officer Freidin Aaron sold $28,082 worth of shares (877 units at $32.02), decreasing direct ownership by 0.31% to 285,143 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    8/20/25 4:23:02 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Director Chase William J was granted 533 shares, increasing direct ownership by 1% to 36,315 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    7/17/25 5:47:43 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    SEC Filings

    View All

    SEC Form 144 filed by GRAIL Inc.

    144 - GRAIL, Inc. (0001699031) (Subject)

    8/15/25 9:07:21 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.

    SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

    8/14/25 1:06:04 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by GRAIL Inc.

    10-Q - GRAIL, Inc. (0001699031) (Filer)

    8/13/25 4:07:42 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on GRAIL with a new price target

    Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

    4/21/25 8:38:45 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Morgan Stanley initiated coverage on GRAIL with a new price target

    Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

    11/27/24 7:29:05 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Wolfe Research initiated coverage on GRAIL

    Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

    11/15/24 7:46:11 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GRAIL Reports Second Quarter 2025 Financial Results

    Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025. Total revenue in the second quarter grew 11% year-over-year to $35.5 million, and Galleri revenue gr

    8/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference

    MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on Wednesday, Aug. 13 at 8:30 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission i

    7/30/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Announce Second Quarter 2025 Financial Results

    MENLO PARK, Calif., July 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Second Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inv

    7/29/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    View All

    GRAIL Appoints Sarah Krevans to Board of Directors

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/14/24 3:35:14 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

    9/30/24 6:42:39 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/10/24 7:45:32 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Financials

    Live finance-specific insights

    View All

    GRAIL Reports Second Quarter 2025 Financial Results

    Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025. Total revenue in the second quarter grew 11% year-over-year to $35.5 million, and Galleri revenue gr

    8/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Announce Second Quarter 2025 Financial Results

    MENLO PARK, Calif., July 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Second Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inv

    7/29/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Reports First Quarter 2025 Financial Results

    Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

    5/13/25 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care